Last reviewed · How we verify
Early postoperative intraperitoneal chemothgerapy
Early postoperative intraperitoneal chemotherapy delivers chemotherapeutic agents directly into the peritoneal cavity immediately after surgery to target residual cancer cells and prevent peritoneal recurrence.
Early postoperative intraperitoneal chemotherapy delivers chemotherapeutic agents directly into the peritoneal cavity immediately after surgery to target residual cancer cells and prevent peritoneal recurrence. Used for Peritoneal carcinomatosis (various primary tumors), Ovarian cancer with peritoneal involvement, Gastric cancer with peritoneal metastases.
At a glance
| Generic name | Early postoperative intraperitoneal chemothgerapy |
|---|---|
| Sponsor | Kyungpook National University Hospital |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This approach combines surgical cytoreduction with regional chemotherapy administration, allowing high local drug concentrations in the peritoneal cavity while minimizing systemic exposure. The timing immediately after surgery targets microscopic residual disease before tumor cells establish themselves, potentially improving local control and overall survival in peritoneal malignancies.
Approved indications
- Peritoneal carcinomatosis (various primary tumors)
- Ovarian cancer with peritoneal involvement
- Gastric cancer with peritoneal metastases
Common side effects
- Abdominal pain
- Peritonitis or infection
- Bowel perforation
- Systemic chemotherapy toxicity
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |